Skip to main content

BioArctic

BioArctic AB is a Swedish biopharmaceutical company that develops biological therapeutics targeting neurodegenerative central nervous system disorders. The company focuses on research and development of disease-modifying antibody therapies for conditions such as Alzheimer's disease and Parkinson's disease. Revenue is primarily driven by upfront licensing fees, development milestone payments, and ongoing sales royalties from global pharmaceutical commercial partners. Its target end market consists of global healthcare providers, hospitals, and patients affected by progressive neurodegenerative illnesses. The company's most prominent product is lecanemab, a disease-modifying Alzheimer's treatment commercialized through a partnership with Eisai. BioArctic maintains a prominent position within the Nordic biotechnology sector due to its proprietary antibody technology platforms. The company is headquartered in Stockholm, Sweden, and its equity is listed on Nasdaq Stockholm.

26 of the funds FundTelligence covers report a position in BioArctic.

Legal name
BioArctic AB
Sector
Health Care
Country
Sweden
Funds holding it
26
Exposure themes
Ageing & Longevity, Age-Related Disease, Neurodegeneration

Funds holding BioArctic

Showing the 8 largest of 26 funds holding it.

Loading...